🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction

Recruitingn/aAges 19 Years - 80 YearsMalePharmicell Co., Ltd.
NCT07431008 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants who previously participated in the parent clinical trial and received the cell therapy (Cellgram-ED). * Participants who have provided written informed consent to participate in this safety follow-up study. Exclusion Criteria:
💊

What it tests

  • Not listed
📍

Where

4 sites
Asan medical center
Seoul, South Korea
Ewha womans university medical center
Seoul, South Korea
Samsung medical center
Seoul, South Korea
Seoul ST. Mary's hospital
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy